Merck (MRK) said Tuesday that it has begun construction of $1 billion biologics facility in Wilmington, Delaware.
The laboratory component of the site, which spans 470,000 square feet at the Chestnut Run Innovation & Science Park, is anticipated to be operational by 2028, with investigational compound production beginning in 2030, the company said.
Merck said it plans to produce its immunotherapy drug Keytruda at the facility for US patients.
The company said it plans to invest $3.5 billion in biologics and small molecule manufacturing facilities in the US over the next four years.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.